From NASDAQ.:

In 2023, CRISPR Therapeutics stock rose by 54%, driven by positive news developments. A biologics-licensing application to the U.S. Food and Drug Administration signaled a step forward. However, amid the mid-year stock slide, Cathie Wood’s ETF sold CRISPR positions, causing investor hesitation. The stock market picked up toward the end of the year. CRISPR obtained regulatory clearance in the UK for its first treatment, and the FDA cleared it for treatment of sickle cell anemia and beta thalassemia in the United States. The exposure paves the way for further market disruption spearheaded by CRISPR.



Read more: Here’s Why CRISPR Therapeutics Stock Rose 54% Last Year